Status:
ACTIVE_NOT_RECRUITING
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors
Lead Sponsor:
Queen's University, Belfast
Conditions:
Anthracycline Induced Cardiotoxicity
Eligibility:
All Genders
18+ years
Brief Summary
Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk. One study showe...
Detailed Description
CLINICAL APPOINTMENT A linked anonymised Case Report Form will be completed using participant answers and relevant aspects of their electronic care record. This will involve questions about the patien...
Eligibility Criteria
Inclusion
- Male and female patients over the age of 18 who have received at least moderate (100mg/m2) anthracycline chemotherapy as a child (\<16 years).
Exclusion
- patients born with complex heart disease
- patients who would not be safely able to have a magnetic resonance imaging scan
- patients who cannot give consent
- patients under the age of 18 or who have had less than a moderate dose of anthracycline
Key Trial Info
Start Date :
October 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2024
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT04852965
Start Date
October 20 2021
End Date
April 1 2024
Last Update
February 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Belfast Health and Social Care Trust
Belfast, United Kingdom, BT9 7AB